Sacituzumab Govitecan for Advanced HER2-Negative Breast Cancer
Part of Cancer, Skin clinical trials.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years
- Metastatic (advanced) breast cancer that is HER2-negative, confirmed by imaging or biopsy
- Previous cancer treatment: for triple-negative breast cancer, at least 1 prior therapy; for hormone-receptor positive breast cancer, prior endocrine therapy and CDK4/6 inhibitors plus at least 1 other therapy
- Good overall health status (able to perform light daily activities; ECOG performance status ≤2)
- At least one measurable tumor on CT or MRI scan
- Adequate bone marrow, liver, and kidney function on blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is tracking how people with metastatic triple-negative breast cancer feel and function during treatment with sacituzumab govitecan or other chemotherapy. It aims to understand real-world benefits from the patient's perspective.
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
This trial tests a drug called Sacituzumab Govitecan for people with HR+/HER2- advanced or metastatic breast cancer that has stopped responding to a CDK4/6 inhibitor. It looks at whether the drug can slow down the cancer and requires you to have a tumor biopsy.
This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.
This trial tests a new drug, Sacituzumab Govitecan, for people with advanced triple-negative breast cancer that hasn't been treated yet. The goal is to see if it can shrink tumors or slow the cancer's growth.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.